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fractionation. The purpose of this study was to define the 
maximum tolerated dose of an hypofractionated RT 
treatment based on IGRT-IMRT-SIB technique with final boost 
by IGRT-stereo-VMAT technique. 
Materials and Methods: Intermediate-high risk CAP patients 
(NCCN categories) were enrolled in consecutive cohorts 
treated with increasing RT doses. In the first cohort patients 
received a dose of 45 Gy (1,8 Gy/fraction) on pelvic lymph 
nodes and a concurrent boost with total dose of 65 Gy (2,6 
Gy/fraction) on prostate +/- seminal vesicles, using IMRT-SIB 
technique after implantation of intraprostatic fiducials. In 
the second cohort patients also received a final boost of 5 Gy 
in single fraction with stereotactic-VMAT technique. An 
adjuvant hormone therapy of 6 (intermediate risk) and 24 
months (high risk) was prescribed. Proctoscopy was 
performed to evaluate rectal toxicity using the Wachter-
Score one year after the end of RT. The study design allowed 
dose escalation in case of < 3/25 (12%) evaluable patients 
with Wachter-score > 3. 
Results: Sixty patients were recruited in the first cohort and 
139 patients in the second cohort (total: 199 patients; 
median age: 73 years (range: 50-82); median PSA: 8,7 ng/ml 
(range: 0,15-83,0); cT3-4: 41,8%; Gleason score > 7: 29,6%). 
The 3-year biochemical recurrence-free survival was 91,6%. 
The analysis results are reported in the table. 
Conclusions: In a dose-escalation study, the use of IGRT-
VMAT-SIB technique with hypofractionated total dose of 65 
Gy resulted feasible in terms of acute and late toxicity, with 
positive preliminar results in terms of biochemical control. 
Stereotactic boost (with total dose of 70 Gy) did not increase 
toxicity rates.  
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Purpose/Objective: Some evidence suggests that there is a 
significant correlation between acute and late rectal toxicity 
after radiotherapy. The purpose of this analysis is to test this 
hypothesis in a large sample of patients (597), treated with 
adjuvant radiotherapy (RT) +/- hormonal therapy (HT). 
Materials and Methods: The results, in terms of acute and 
late toxicity, were analyzed and compared in a population of 
patients enrolled in 8 different clinical studies. Acute toxicity 
was evaluated according to the RTOG scale and late toxicity 
was evaluated according to the RTOG-EORTC scale. The 
cumulative actuarial late toxicity was calculated using the 
Kaplan-Meier method and comparison of survival curves was 
performed by logrank test (univariate analysis) and Cox's 
proportional hazard method (multivariate analysis, using as a 
covariate: radiotherapy dose, fractionation, prophylactic 
lymph node irradiation, adjuvant hormonal therapy ). 
Results: 597 patients, treated with radiotherapy were 
evaluated; 91.5% of patients received adjuvant hormonal 
therapy (LH-RH analogue: 49,9%; antiandrogen agent 
[bicalutamide, 150 mg per day]: 41.6%). The results of 
statistical analysis are shown in the table. There is a 
statistical correlation between acute and grade 1 and 2 late 
rectal toxicity, both at univariate and multivariate analysis. 
 
 
Conclusions: The results of this analysis confirm the close 
correlation between acute and late radio-induced rectal 
toxicity. These results suggest that excessive early damage to 
the 'acute-respoding' component of the rectal wall plays an 
important role in the genesis of late toxicity. Radiation 
proctitis is thus confirmed, at least in part, as a 
'consequential' effect. This justifies the use of acute toxicity 
as surrogate end-point of late complications in dose-finding 
studies on radiation therapy of prostate cancer.  
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Purpose/Objective: Traditionally, seminal vesicle invasion 
(T3b) was diagnosed by digital rectal examination or 
transrectal ultrasound. In the recent years diagnostic MRI has 
become available, a technique that is much more sensitive 
and can detect even minimal invasion. It is, however, unclear 
whether a MRI based T3b (MR-T3b) has the same poor 
prognosis as a clinically staged T3b (cT3b). We therefore 
compared the clinical outcome of MR T3b with that of cT3b 
prostate carcinoma (PC). 
Materials and Methods: Patients (n=90, cohort A) were 
treated with (78 Gy) image-guided IMRT for localized PC 
between 2008 – 2010 and had diagnostic signs of SV invasion 
on the planning MRI; 60 % was prescribed 3y of adjuvant 
hormonal treatment (AHT) because of clinical high-risk 
features. Pre-RT screening for positive LN was performed. 
Patient and tumor characteristics were compared with a 
previous cohort B (n=87) treated in 1997 – 2002 (68 Gy or 78 
Gy) with 3D conformal RT (32 % received 3y AHT). Freedom 
from failure (FFF) was scored according the Phoenix 
definition. Multivariate Cox regression (MV) was applied to 
determine significant predictive factors for freedom from 
failure (FFF). 
